Hikma launches Levophed generic
Hikma is introducing norepinephrine bitartrate injection, a generic of Levophed. The drug will be available in 4 mg/4 ml dosage strength.
The product is indicated for blood pressure control in certain acute hypotensive states and as an adjunct in the treatment of cardiac arrest and profound hypotension.
Norepinephrine bitartrate injection had a market value of approximately $97 million for the 12 months ending January 2019, according to IQVIA.
“The launch of norepinephrine bitartrate injection in the U.S. is the latest example of how Hikma is continuing to expand its comprehensive portfolio of quality injectable medicines available to U.S. hospitals. We are committed to providing quality medicines to doctors and their patients and intend to continue identifying and launching injectable medicines that meet the growing needs of U.S. hospitals and clinics,” Hikma president of injectables Riad Mechlaoui said.
The product is indicated for blood pressure control in certain acute hypotensive states and as an adjunct in the treatment of cardiac arrest and profound hypotension.
Norepinephrine bitartrate injection had a market value of approximately $97 million for the 12 months ending January 2019, according to IQVIA.
“The launch of norepinephrine bitartrate injection in the U.S. is the latest example of how Hikma is continuing to expand its comprehensive portfolio of quality injectable medicines available to U.S. hospitals. We are committed to providing quality medicines to doctors and their patients and intend to continue identifying and launching injectable medicines that meet the growing needs of U.S. hospitals and clinics,” Hikma president of injectables Riad Mechlaoui said.